ArticlePloS one2020
Inexpensive, non-invasive biomarkers predict Alzheimer transition using machine learning analysis of the Alzheimer's Disease Neuroimaging (ADNI) database.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Applying machine learning to high-dimensional proteomics datasets for the identification of Alzheimer's disease biomarkers.Fluids and barriers of the CNS · 2025Article
- Non-Invasive Biomarkers in the Era of Big Data and Machine Learning.Sensors (Basel, Switzerland) · 2025Review
- Gut microbiome predicts cognitive function and depressive symptoms in late life.Molecular psychiatry · 2024Article
- Prediction of future dementia among patients with mild cognitive impairment (MCI) by integrating multimodal clinical data.Heliyon · 2024Article
- Potential Benefits of Using Artificial Intelligence to Diagnose Alzheimer's Disease.Journal of clinical neurology (Seoul, Korea) · 2024Article
- Mapping Knowledge Landscapes and Emerging Trends in AI for Dementia Biomarkers: Bibliometric and Visualization Analysis.Journal of medical Internet research · 2024Article
- Understanding machine learning applications in dementia research and clinical practice: a review for biomedical scientists and clinicians.Alzheimer's research & therapy · 2024Review
- AI-Assisted Detection of Biomarkers by Sensors and Biosensors for Early Diagnosis and Monitoring.Biosensors · 2024Review
- A machine learning approach for identifying anatomical biomarkers of early mild cognitive impairment.PeerJ · 2024Article
- Artificial intelligence for biomarker discovery in Alzheimer's disease and dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Review
- Deep causal feature extraction and inference with neuroimaging genetic data.Statistics in medicine · 2023Article
- An Alzheimer's disease category progression sub-grouping analysis using manifold learning on ADNI.Scientific reports · 2023Article
- Neuropsychiatric Symptoms and Commonly Used Biomarkers of Alzheimer's Disease: A Literature Review from a Machine Learning Perspective.Journal of Alzheimer's disease : JAD · 2023Review
- A multi-expert ensemble system for predicting Alzheimer transition using clinical features.Brain informatics · 2022Article
- The Road to Personalized Medicine in Alzheimer's Disease: The Use of Artificial Intelligence.Biomedicines · 2022Review
- Data-Driven Analyses of Longitudinal Hippocampal Imaging Trajectories: Discrimination and Biomarker Prediction of Change Classes.Journal of Alzheimer's disease : JAD · 2022Article
- Predicting AT(N) pathologies in Alzheimer's disease from blood-based proteomic data using neural networks.Frontiers in aging neuroscience · 2022Article
- Association of peripheral blood DNA methylation level with Alzheimer's disease progression.Clinical epigenetics · 2021Article
- Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer's disease.Alzheimer's research & therapy · 2021Article
- Developing the ATX(N) classification for use across the Alzheimer disease continuum.Nature reviews. Neurology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The Alzheimer's Disease Neuroimaging (ADNI) database is an expansive undertaking by government, academia, and industry to pool resources and data on subjects at various stage of symptomatic severity due to Alzheimer's disease. As expected, magnetic resonance imaging is a major component of the project. Full brain images are obtained at every 6-month visit. A range of cognitive tests studying executive function and memory are employed less frequently. Two blood draws (baseline, 6 months) provide samples to measure concentrations of approximately 145 plasma biomarkers. In addition, other diagnostic measurements are performed including PET imaging, cerebral spinal fluid measurements of amyloid-beta and tau peptides, as well as genetic tests, demographics, and vital signs. ADNI data is available upon review of an application. There have been numerous reports of how various processes evolve during AD progression, including alterations in metabolic and neuroendocrine activity, cell survival, and cognitive behavior. Lacking an analytic model at the onset, we leveraged recent advances in machine learning, which allow us to deal with large, non-linear systems with many variables. Of particular note was examining how well binary predictions of future disease states could be learned from simple, non-invasive measurements like those dependent on blood samples. Such measurements make relatively little demands on the time and effort of medical staff or patient. We report findings with recall/precision/area under the receiver operator curve after application of CART, Random Forest, Gradient Boosting, and Support Vector Machines, Our results show (i) Random Forests and Gradient Boosting work very well with such data, (ii) Prediction quality when applied to relatively easily obtained measurements (Cognitive scores, Genetic Risk and plasma biomarkers) achieve results that are competitive with magnetic resonance techniques. This is by no means an exhaustive study, but instead an exploration of the plausibility of defining a series of relatively inexpensive, broad population based tests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.